The proposed bill enacts several new sections of the Revised Code aimed at facilitating individualized investigational treatments for patients suffering from life-threatening or severely debilitating illnesses. Key definitions are established, including "eligible facility," "eligible patient," and "individualized investigational treatment," which refers to treatments tailored to an individual's unique genetic profile. The bill outlines the conditions under which eligible patients can request such treatments from manufacturers operating within eligible facilities, emphasizing that while manufacturers may provide these treatments, they are not obligated to do so. Additionally, it specifies that eligible facilities can offer these treatments without compensation, although patients may be required to cover associated costs.

The bill also details the process for obtaining informed consent from patients before administering individualized investigational treatments, including the necessary documentation and disclosures that must be provided to patients. It protects physicians from disciplinary actions based solely on their recommendations for these treatments and ensures that patients' heirs are not liable for any debts related to the treatment if the patient passes away. Furthermore, the bill clarifies that it does not create a private cause of action against manufacturers or other entities involved in the treatment process, provided they comply with the established regulations. Overall, the legislation aims to enhance access to potentially life-saving treatments while ensuring patient safety and informed consent.